GV.PA Genomic Vision SA EURONEXT €0.0018 on 19 Jan 2026: Volume surge signals active intraday interest

GV.PA stock is trading at €0.0018 on EURONEXT in an active intraday session on 19 Jan 2026. The share is up 5.88% from yesterday and volume has surged to 38,489,238 shares versus an average of 14,217,513. That makes GV.PA one of the most active small-caps on the European market this morning. We examine what the volume spike means for liquidity, how fundamentals stack up, and where short-term priceaction could head for Genomic Vision SA.

GV.PA stock intraday snapshot and trade drivers

Genomic Vision SA (GV.PA) opened at €0.0018 and has traded between €0.0015 and €0.0020 today. Market cap stands at €693,191 and shares outstanding total 385,105,984. The intraday move coincides with a relative volume spike of 2.71x the average, underlining real-time investor interest.

High volume in a micro-cap often reflects news flow, block trades, or active retail interest. No fresh company release is in the public feed; the current trade appears driven by momentum and liquidity dynamics rather than a new earnings report.

GV.PA stock volume and liquidity: why most active matters

Volume is the defining feature of this intraday report. Today’s 38,489,238 shares traded compare with a 50-day price average of €0.004844 and a 200-day average of €0.013997. The stock’s average volume is 14,217,513, so the current flow increases tradability but also raises short-term volatility.

For traders focused on the most active names, higher liquidity can narrow spreads. For long-term investors, however, the elevated trading does not change the company’s small market cap or thin balance-sheet reality.

GV.PA stock fundamentals and valuation metrics

Genomic Vision’s trailing EPS is -0.11 and the reported PE is negative. Key ratios show a price-to-sales of 0.47 and price-to-book around -0.19, reflecting negative equity. Cash per share is €0.00557 and enterprise value is approximately €2,369,191. The current ratio is 0.91, indicating working-capital pressure.

Revenue per share is 0.01085, free cash flow per share is -0.03307, and research spending is high at over 200% of revenue on a TTM basis. These metrics show a development-stage diagnostics firm with sizeable R&D intensity and persistent losses.

GV.PA stock technicals and Meyka AI grade

Price momentum is weak versus longer-term averages: 50-day average €0.00484 and 200-day average €0.013997, both well above today’s price. Day range €0.0015–€0.0020 signals tight intraday swings but elevated trading volume.

Meyka AI rates GV.PA with a score out of 100. Meyka AI rates GV.PA with a score out of 100: 58.67, Grade C+, Suggestion HOLD. This grade factors in S&P 500 and sector benchmarks, industry comparison, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The rating highlights caution due to negative equity and volatile liquidity, while acknowledging technology and partnership potential.

GV.PA stock risks and sector context

Genomic Vision operates in Healthcare, Medical – Diagnostics & Research. The sector average current ratio is 2.15; GV.PA’s 0.91 underperforms. Key risks include negative equity, thin market cap €693,191, and months of cash runway if revenue does not scale.

The company lists partnerships with Quest Diagnostics and research links to Institut Pasteur. Those relationships represent upside, but the small team of 33 employees means execution risk is material. Debt-to-market-cap ratios are elevated, and interest coverage is negative, underscoring balance-sheet vulnerability.

GV.PA stock trading strategy and price targets

For intraday traders, treat GV.PA as a high-beta micro-cap. Tight stop discipline and limit orders are essential given low absolute prices. Watch the €0.0020 intraday cap and €0.0014–€0.0015 as near-term support.

Meyka AI’s forecast model projects a near-term reference price target of €0.0050 and a medium-term scenario target of €0.0200 versus the current €0.0018. That implies upside of +177.78% to €0.0050 and +1,011.11% to €0.0200. Forecasts are model-based projections and not guarantees. Use size limits and risk controls when trading micro-cap names.

Final Thoughts

GV.PA stock is one of the most active micro-cap names on EURONEXT this intraday session, trading at €0.0018 on 19 Jan 2026 with 38,489,238 shares changing hands. The volume surge improves short-term liquidity but does not erase structural risks: negative EPS (-0.11), negative equity, low current ratio (0.91), and a tiny market cap (€693,191). Meyka AI rates GV.PA with a score out of 100: 58.67 (Grade C+, Suggestion HOLD). That grade balances sector potential against weak financials.

For active traders the price action offers volatility and tradable ranges around €0.0015–€0.0020. For investors, Meyka AI’s forecast model projects a near-term reference of €0.0050 (+177.78% vs €0.0018) and a medium-term scenario of €0.0200 (+1,011.11%). These targets reflect recovery scenarios tied to product adoption and partnerships. Forecasts are model-based projections and not guarantees. Monitor cash position, partnership progress, and any company announcements. For intraday trading, use tight risk controls; for longer horizons, wait for clearer evidence of revenue growth and balance-sheet repair.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.